-transparent.png){kind=logo}
The activity of the antiestrogen tamoxifen was evaluated in 23 patients with epithelial ovarian carcinoma. All patients had received cytotoxic chemotherapy. The patients were given daily doses of 20 or 40 mg tamoxifen orally for a minimum of eight weeks. No objective tumor regressions were noted. In 19 patients disease remained stable for a median duration of 17 weeks (range: eight to 47 weeks). Estrogen and/or progesterone levels available for six patients did not correlate with stability of disease. The authors conclude that tamoxifen does not induce objective response in patients with epithelial ovarian carcinoma who have been treated with cytotoxic chemotherapy. However, in the current study about 80% of such patients had short-lived objective stabilization of their disease.
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
June 1987,
Gynecologic oncology,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
July 1995,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
May 1982,
Obstetrics and gynecology,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
January 2007,
Medical oncology (Northwood, London, England),
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
September 2005,
British journal of cancer,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
January 2012,
Current pharmaceutical design,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
March 1991,
The New England journal of medicine,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
March 1994,
Obstetrics and gynecology clinics of North America,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
June 2000,
Endocrine-related cancer,
D R Shirey, and
J J Kavanagh, and
D M Gershenson, and
R S Freedman, and
L J Copeland, and
L A Jones
September 2008,
Current opinion in oncology,
